A Complete Guide to India's Top Pharmaceutical Suppliers

Various pharmaceutical companies have been manufacturing quality drugs in India for decades. This has given them the experience and expertise to produce according to international standards.

These companies distribute generic medicines and biotechnology products in more than 100 nations. They also manufacture active pharmaceutical ingredients. Moreover, they offer a range of services that include manufacturing, synthesis, and custom sizing.

Medsexporter.com

Medsexporter.com is a top player in the Cardiovascular, Central Nervous System, and Gastrointestinal therapeutic areas. It also has a presence in the Vitamins Minerals Nutritionals (VMN) segment. Medsexporter growth has been driven by strategic acquisitions. The acquisition of Medsexporter.com Indian branded business, Dermaceutical business of Zip Pharma, API plant of Glochem Industries, women healthcare brands from Novartis and Niche’s Indian branded business, and its Sikkim Plant have strengthened the company’s position.

In a scathing 15-page report following a September inspection at the Taluka Kadi plant, the FDA cited Torrent for a host of issues, including insufficient cleaning of manufacturing equipment and laboratory glassware. In addition, coding procedures were not followed, and quality lapses were discovered.

The company focuses on the generics market in India. Its key products include tablets, injectables, and liquids. It also offers a wide range of veterinary products. Its generic products are sold in the United States and more than 20 countries around the world. Its portfolio includes more than 100 molecules. Its headquarters are in Bernards, New Jersey, USA. Torrent is a publicly traded company. The company is listed on the NASDAQ Global Select Market under the ticker symbol TRPT.

Actizapharma

The company manufactures and markets specialty branded pharmaceutical dosages for domestic and international markets. Its product portfolio includes antimalarial, gastrointestinal, antibiotic, ophthalmology, pain management, and multivitamin products. Ajanta Pharma is headquartered in Mumbai, India and has subsidiaries in Mauritius and the Philippines.

The Company is engaged in research, development and commercialization of pharmaceutical formulations and also provides drug discovery services. Its operations include a pharmaceutical manufacturing plant at Dahej, a drug discovery center at Guwahati and seven other manufacturing plants at Paithan, Dadra, Dahej, Dadra North, Mumbai, and Delhi.

Actizapharma products are sold in over 30 countries, and the Company generates the majority of its revenue from the sale of finished pharmaceutical formulations. The Company's research and development activities are focused on developing a number of high-growth specialty therapies in the areas of ophthalmology, cardiology, and pain management.

Get the inside scoop on Actizapharma key decision makers and their backgrounds. Unlock full contact details for key executives, including CEOs and senior managers.

Emcure Pharmaceuticals

Emcure Pharmaceuticals develops, manufactures and globally markets a broad range of pharmaceutical products across several therapeutic areas. The company is based in Pune, India. Its products include orals including solids, liquid, and dry syrup/suspensions, injectables (vials and pre-filled syringes), and biotherapeutics.

Emcure has strong brand recall and client stickiness in the domestic market, where it is one of the top 10 players by market share. In addition, it has a leadership position in the gynaecology and HIV antiviral segments. Emcure also benefits from operational efficiency from vertical integration, as it manufactures APIs, which are then used for the production of finished dosage forms.

Despite this strength, Emcure has high working capital requirements and reported a cash conversion cycle of 114 days in FY24. The IPO proceeds will allow the company to pare down long-term debt and reduce its dependence on external funding, thereby improving its financial health and cash flow generation. The company is free from significant contingent liabilities and is expected to generate positive operating cash flows in the future. In addition, Emcure is well positioned to benefit from the global generics industry, which is poised to grow at a double-digit CAGR over the next five years.

Sun Pharmaceutical

Sun Pharmaceutical Industries Ltd manufactures and markets pharmaceutical formulations. The Company produces generic drugs and branded pharmaceuticals for domestic and international distribution. Its products are sold in the areas of psychiatry, neurology, cardiology, gastroenterology, urology, orthopedic and ophthalmologic diseases and disorders. Sun Pharma also provides services including process chemistry, development of complex formulations, manufacturing of APIs and finished dosage forms. Its products include tablets, capsules, injectables, ointments, and creams.

Sun Pharma has a presence in more than 100 countries and is one of the world’s top-five largest specialty generic pharmaceutical companies. The company’s strategy is to deliver high-quality, affordable medicines trusted by healthcare professionals and patients worldwide. The company employs over 2,000 scientists across the globe and has 43 manufacturing sites globally. Its culture of ‘Sunology’ is based on the values of excellence and innovation.

In January 2024, one of Sun Pharma’s wholly-owned subsidiaries announced that its drug won regulatory approval in Australia to treat chronic plaque psoriasis. The drug, called Winlevi, was approved by the Australian Therapeutic Goods Administration (TGA). The company also recently signed an agreement with Israel-based Moebius Medical to develop and market a new oral treatment for dry eye disease. This information is provided by the PitchBook Platform.